ExploreWatchlistsPricing
  1. JP-listed companies
  2. Takeda Pharmaceutical Company Limited
  3. Financials
  4. Total current liabilities

Takeda Pharmaceutical Company Limited (4502)

Market cap
¥8.92T
P/E ratio
57.3x
Takeda develops and manufactures innovative medicines for gastrointestinal diseases, rare diseases, oncology, neuroscience, vaccines, and plasma therapies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal current liabilities (Million JPY)YoY (%)
Mar 31, 20252,506,521+8.36%
Mar 31, 20242,313,103-6.80%
Mar 31, 20232,481,940+15.67%
Mar 31, 20222,145,730+21.01%
Mar 31, 20211,773,176-18.51%
Mar 31, 20202,175,898-13.34%
Mar 31, 20192,510,931+609.22%
Mar 31, 2018354,039-60.72%
Mar 31, 2017901,241+70.36%
Mar 31, 2016529,032+10.65%
Mar 31, 2015478,099

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat